Evidence map›Paper›PMID 35367668›Full record

ArticleMolecular metabolism2022

Fibroblast growth factor 19 stimulates water intake.

José Ursic-Bedoya, Carine Chavey, Guillaume Desandré, Lucy Meunier, Anne-Marie Dupuy, Iria Gonzalez-Dopeso Reyes, Thierry Tordjmann, Eric Assénat, Urszula Hibner, Damien Gregoire

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025
    Review
  3. Article
  4. Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

José Ursic-BedoyaInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France; Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, University of Montpellier, France.
Carine ChaveyInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Guillaume DesandréInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Lucy MeunierInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France; Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, University of Montpellier, France.
Anne-Marie DupuyBiochemistry and Hormonology Department, Lapeyronie Hospital, University of Montpellier, Montpellier, France.
Iria Gonzalez-Dopeso ReyesInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Thierry TordjmannUniversité Paris Saclay, Faculté des Sciences d'Orsay, INSERM U.1193, Bât. 443, 91405, Orsay, France.
Eric AssénatInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France; Department of Hepatogastroenterology, Hepatology and Liver Transplantation Unit, Saint Eloi Hospital, University of Montpellier, France.
Urszula HibnerInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Damien GregoireInstitut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France. Electronic address: damien.gregoire@igmm.cnrs.fr.
Centre National de la Recherche Scientifique · FRInserm · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor 19 (FGF19) is a hormone with pleiotropic metabolic functions, leading to ongoing development of analogues for treatment of metabolic disorders. On the other hand, FGF19 is overexpressed in a sub-group of hepatocellular carcinoma (HCC) patients and has oncogenic properties. It is therefore crucial to precisely define FGF19 effects, notably in the context of chronic exposure to elevated concentrations of the hormone. Here, we used hydrodynamic gene transfer to generate a transgenic mouse model with long-term FGF19 hepatic overexpression. We describe a novel effect of FGF19, namely the stimulation of water intake. This phenotype, lasting at least over a 6-month period, depends on signaling in the central nervous system and is independent of FGF21, although it mimics some of its features. We further show that HCC patients with high levels of circulating FGF19 have a reduced natremia, indicating dipsogenic features. The present study provides evidence of a new activity of FGF19, which could be clinically relevant in the context of FGF19 overexpressing cancers and in the course of treatment of metabolic disorders by FGF19 analogues.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsDrinkingFibroblast Growth FactorsHormonesHumansMiceReceptor, Fibroblast Growth Factor, Type 4fibroblast growth factor 15, mouseFibroblast Growth FactorsHormonesReceptor, Fibroblast Growth Factor, Type 4EndocrineFGFR4Hepatocellular carcinomaHydrodynamic gene transferLiver

Identifiers

PMID35367668
PMCPMC9019402
OpenAlexW4220893285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.